Exelixis
EXEL
#2083
Rank
โ‚ฌ6.91 B
Marketcap
24,26ย โ‚ฌ
Share price
0.22%
Change (1 day)
21.38%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total assets

Total assets on the balance sheet as of June 2024 : โ‚ฌ2.50 B

According to Exelixis's latest financial reports the company's total assets are โ‚ฌ2.50 B. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

Exelixis - Total assets on balance sheet (from 2001 to 2024)

Total assets by year

Year Total assets Change
2023-12-31โ‚ฌ2.66 B-7.05%
2022-12-31โ‚ฌ2.86 B24.52%
2021-12-31โ‚ฌ2.29 B31.52%
2020-12-31โ‚ฌ1.74 B4.11%
2019-12-31โ‚ฌ1.67 B35.26%
2018-12-31โ‚ฌ1.24 B127.34%
2017-12-31โ‚ฌ0.54 B-3.57%
2016-12-31โ‚ฌ0.56 B86.05%
2015-12-31โ‚ฌ0.30 B14.63%
2014-12-31โ‚ฌ0.26 B-27.1%
2013-12-31โ‚ฌ0.36 B-33.23%
2012-12-31โ‚ฌ0.54 B80.16%
2011-12-31โ‚ฌ0.30 B11.36%
2010-12-31โ‚ฌ0.27 B13.36%
2009-12-31โ‚ฌ0.23 B-15.74%
2008-12-31โ‚ฌ0.28 B1.83%
2007-12-31โ‚ฌ0.27 B-6.72%
2006-12-31โ‚ฌ0.29 B6.7%
2005-12-31โ‚ฌ0.28 B45.76%
2004-12-31โ‚ฌ0.19 B-32.73%
2003-12-31โ‚ฌ0.28 B-11.71%
2002-12-31โ‚ฌ0.32 B-17.34%
2001-12-31โ‚ฌ0.39 B

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
โ‚ฌ66.29 B 2,549.29%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚ฌ125.51 B 4,915.83%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ101.63 B 3,961.49%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ85.40 B 3,312.98%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ82.03 B 3,178.15%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ163.41 B 6,430.12%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ195.09 B 7,696.02%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ45.49 M-98.18%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ91.35 M-96.35%๐Ÿ‡บ๐Ÿ‡ธ USA